OmniGuide

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

Retrieved on: 
Monday, June 5, 2023
Epilepsy, Seizure, Marketing, OmniGuide, Anatomy, BIRD Foundation, Quality of life, OTCQB, BT, MIT, Medication, Electron-beam technology, MRI, Neurosurgery, Patient, Physician, Algorithm, Engineering, Laser beam machining, Stingray phone tracker, Massachusetts Institute of Technology, Medical imaging, Pharmaceutical industry

An initial area of emphasis of the StingRay System will be for the treatment of epilepsy.

Key Points: 
  • An initial area of emphasis of the StingRay System will be for the treatment of epilepsy.
  • Recognizing the critical need for innovation, BeaMed has developed an advanced laser system designed to revolutionize epilepsy treatment.
  • “Innovation Pharmaceuticals is delighted with the ongoing progress of BeaMed towards creating a groundbreaking product.
  • Previously, Gil led product development and marketing at OmniGuide, a successful high-growth laser based medical device spin-off out of the Massachusetts Institute of Technology (MIT).

Global Vessel Sealing Devices Market Report to 2030 - Featuring Johnson & Johnson, Medtronic, B. Braun Melsungen and Aktiengesellschaft Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Surgery, Health, Medical Devices, Blood, Bipolar, AC, Johnson & Johnson, Innovation Center station, Geography, Olympus Corporation, SWOT, USD, Instrument, OmniGuide, Food preservation, Medtronic

Vessel Sealing Devices are used in non-invasive surgical procedure for cutting, coagulating, separate and seal the blood vessels.

Key Points: 
  • Vessel Sealing Devices are used in non-invasive surgical procedure for cutting, coagulating, separate and seal the blood vessels.
  • The vessel sealing devices have active electrodes that circuits the AC current aiming the target tissue.
  • Various factors such as reliability, efficiency is considered while choosing the appropriate vessel sealing devices.
  • Global Vessel Sealing Devices Market: Segmentation Analysis
    The Global Vessel Sealing Devices Market is segmented based on Application, Product Type, Energy Type, End-User, and Geography.

Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement

Retrieved on: 
Monday, January 9, 2023
Brain, OTC, OmniGuide, PACS, FDA, Knowledge, 3D, Partnership, OEM, MIT, Marketing, BIRD Foundation, Beam-powered propulsion, Massachusetts Institute of Technology, Acceleration, Engineering, Temperature, Epilepsy, MRI, Medical imaging

WAKEFIELD, MA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd. (“Shina”), a company specializing in medical imaging software platforms, in order to build on unique capabilities of Shina and accelerate the development, regulatory clearance, and commercial deployment of BeaMed’s StingRay Laser System for brain surgery.

Key Points: 
  • In addition, special software tools will be developed to leverage the unique laser-based surgical tools developed by BeaMed.
  • Shina brings forward decades of relevant experience in rapid development and deployment of medical imaging software suites, including advanced CT/MRI imaging platforms for strategic health companies.
  • “This agreement provides us with two key strategic advantages,” said Gil Shapira, Chief Executive Officer of BeaMed.
  • Shina Systems Ltd. develops and markets clinical image management, PACS and medical imaging analysis application software for almost 3 decades.

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

Retrieved on: 
Monday, November 28, 2022
Marketing, Epilepsy, OTC, Anatomy, Neurosurgery, General surgery, Engineering, Food, Brain, BIRD Foundation, Patient, BT, Massachusetts Institute of Technology, Food and Drug Administration, Cardiothoracic surgery, Liver, Prostate, MIT, Stingray phone tracker, Neck, Neoplasm, Oral and maxillofacial surgery, OmniGuide, Lung cancer, Cancer, Prostate cancer, Urology, MANTA, Breast cancer, FDA, Breast, Pharmaceutical industry, Medical imaging, Gynaecology, Orthopedic surgery, Arthroscopy, Radiology, Ophthalmology, Particle beam

WAKEFIELD, MA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BT BeaMedical Technologies (“BeaMed”), a private company developing a next-generation laser-based platform for epilepsy and cancer surgery, has notified Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) that it has received U.S. Food and Drug Administration (FDA) clearance (K222701) for its MANTA surgical laser family. The clearance is an important milestone for BeaMed in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality. Innovation Pharmaceuticals made a strategic investment to acquire a minority stake in BeaMed in June 2022.

Key Points: 
  • WAKEFIELD, MA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BT BeaMedical Technologies (BeaMed), a private company developing a next-generation laser-based platform for epilepsy and cancer surgery, has notified Innovation Pharmaceuticals (OTC: IPIX) (the Company) that it has received U.S. Food and Drug Administration (FDA) clearance (K222701) for its MANTA surgical laser family.
  • Innovation Pharmaceuticals made a strategic investment to acquire a minority stake in BeaMed in June 2022.
  • BeaMed expects to soon make requisite submissions to the FDA for clearance of its fiber optics for use in multiple medical indications.
  • Gil Shapira brings forward 26+ years of engineering and product development and management experience, with over 17 years in the surgical laser industry.

European Patent Office Grants OmniGuide with patent for its Laparoscopic Handpiece for FlexAssure CO2 Flexible Instruments and Fibers

Retrieved on: 
Tuesday, September 13, 2022
Medical Supplies, Medical Devices, Health, Surgery, Other Health, General Health, Intellectual property, OmniGuide, Neurology, European Patent Convention, Patent, European Patent Office, Urology, ENT, Dentistry, Gynaecology, Laparoscopy

Laparoscopy is a surgical approach that allows a surgeon to access the inside of the human body without making large incisions.

Key Points: 
  • Laparoscopy is a surgical approach that allows a surgeon to access the inside of the human body without making large incisions.
  • These procedures are widely adopted worldwide for their patient benefits including smaller surgical scars, quicker recovery, and decreased post procedure pain.
  • OmniGuide FlexAssure CO2 Flexible Instruments are utilized in thousands of surgical procedures including Urology, Gynecology, ENT, and Neurology as well as with handheld, laparoscopic, and surgical robots.
  • We are pleased that the European Patent Office has granted this new patent, in line with our continuous investment in minimally invasive surgery and New Product Development stated Robert Allen, OmniGuide CFO and LISA Laser Products Managing Director OmniGuide has the widest portfolio of CO2 Flexible Instruments and Fibers, uniquely designed to meet minimally invasive surgical needs.

OmniGuide Holdings Receives FDA Clearance for RevoLix™ HTL Hybrid Thulium Laser for the treatment of BPH and Stones

Retrieved on: 
Thursday, May 26, 2022
FDA, General Health, Health, Medical Devices, Digital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Urine, Multimedia, Patient, Gold, View, BPH, OGH, Patent, FDA, RA, Global marketing, Safety, Technology, Laser, HTL, Thulium, OmniGuide, Therapy, Medical device

OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures.

Key Points: 
  • OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures.
  • At the same time, patent pending HTL technology allows for stone clearance without overheating stone and urine medium.
  • The FDA cleared Revolix HTL, LISA Laser GmbH a Division of OmniGuide Holdings Inc., through the 510(k) premarket clearance pathway.
  • With over 600 peer reviewed clinical articles and 31 years of surgical Thulium laser research and development experience, RevoLix and OmniGuide look forward to serving patients and their Urologist here in the United States, said Carlos Acosta Global Director of RA QA OmniGuide Holdings.

OmniGuide Receives 510(k) FDA Clearance for OTO-U Otology CO2 Surgical Fiber

Retrieved on: 
Wednesday, January 20, 2021
Technology, Surgery, Medical devices, FDA, Nanotechnology, Clinical trials, Biotechnology, Health, Pharmaceutical, Medicine, Clinical medicine, Medical specialties, Endoscopy, Digestive system surgery, Laparoscopy, OmniGuide, Minimally invasive procedure, Surgery, Surgical specialties

OmniGuide Holdings, a global healthcare technology leader in the design and delivery of innovative solutions for medical and surgical procedures, announces the commercial launch of the NEW OTO-U CO2 Laser System Fiber, designed for ENT and Otology Surgeons.

Key Points: 
  • OmniGuide Holdings, a global healthcare technology leader in the design and delivery of innovative solutions for medical and surgical procedures, announces the commercial launch of the NEW OTO-U CO2 Laser System Fiber, designed for ENT and Otology Surgeons.
  • We understand the need for an everyday CO2 surgical fiber to complement our Flexible Instrument Portfolio Matthew Henderson, President and CEO of OmniGuide Holdings Next generation innovation is something OmniGuide can deliver.
  • OTO-U surgical fiber is the outcome of a multiple year investment in product development to meet the needs of the versatile CO2 surgical fiber user, with the right balance between price and performance, for everyday otology surgical procedures, said Matthew Rice OmniGuide Managing Director.
  • OmniGuide Surgical, a leader in flexible fiber CO2 laser technology, offers a range of products designed to enhance surgical accuracy, access and control for minimally invasive surgery, laparoscopy and robotic-assisted surgery.